Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 15, 2024

BUY
$0.46 - $0.78 $15,798 - $26,788
34,344 New
34,344 $18,000
Q2 2023

Aug 11, 2023

BUY
$0.98 - $1.11 $19,595 - $22,194
19,995 Added 193.67%
30,319 $31,000
Q1 2023

May 16, 2023

SELL
$0.98 - $1.06 $3,048 - $3,297
-3,111 Reduced 23.16%
10,324 $10,000
Q4 2022

Feb 14, 2023

BUY
$0.96 - $28.0 $12,897 - $376,180
13,435 New
13,435 $13,000
Q2 2022

Aug 15, 2022

BUY
$1.07 - $1.55 $96,491 - $139,777
90,179 Added 327.51%
117,714 $153,000
Q1 2022

May 16, 2022

SELL
$1.21 - $2.24 $52,712 - $97,583
-43,564 Reduced 61.27%
27,535 $40,000
Q4 2021

Feb 14, 2022

SELL
$2.02 - $3.36 $309,308 - $514,493
-153,123 Reduced 68.29%
71,099 $152,000
Q3 2021

Nov 15, 2021

BUY
$2.96 - $36.67 $663,697 - $8.22 Million
224,222 New
224,222 $664,000
Q2 2021

Aug 11, 2021

SELL
$31.5 - $42.5 $1.66 Million - $2.23 Million
-52,546 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$25.01 - $40.24 $1.31 Million - $2.11 Million
52,546 New
52,546 $1.8 Million
Q4 2020

Feb 16, 2021

SELL
$28.66 - $46.79 $129,199 - $210,929
-4,508 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$14.71 - $50.69 $66,312 - $228,510
4,508 New
4,508 $219,000

Others Institutions Holding FBRX

# of Institutions
1
Shares Held
175K
Call Options Held
0
Put Options Held
0

About Forte Biosciences, Inc.


  • Ticker FBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,340,300
  • Market Cap $114M
  • Description
  • Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
More about FBRX
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.